A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

NCT02413827 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Feasibility concerns due to changes in standard of care

Conditions

Unresectable Stage III or Stage IV Melanoma

Interventions

DRUG: Combination of varlilumab and ipilimumab
DRUG: Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC

Sponsor

Celldex Therapeutics